- Home
- URGN vs EOI Comparison
URGN vs EOI Comparison
Compare URGN & EOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- EOI
- Stock Information
- Founded
- URGN 2004
- EOI 2004
- Country
- URGN United States
- EOI United States
- Employees
- URGN N/A
- EOI N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- EOI Finance/Investors Services
- Sector
- URGN Health Care
- EOI Finance
- Exchange
- URGN Nasdaq
- EOI Nasdaq
- Market Cap
- URGN 831.6M
- EOI 819.4M
- IPO Year
- URGN 2017
- EOI N/A
- Fundamental
- Price
- URGN $19.22
- EOI $20.95
- Analyst Decision
- URGN Strong Buy
- EOI
- Analyst Count
- URGN 8
- EOI 0
- Target Price
- URGN $29.00
- EOI N/A
- AVG Volume (30 Days)
- URGN 1.3M
- EOI 83.6K
- Earning Date
- URGN 08-07-2025
- EOI 01-01-0001
- Dividend Yield
- URGN N/A
- EOI 7.19%
- EPS Growth
- URGN N/A
- EOI N/A
- EPS
- URGN N/A
- EOI N/A
- Revenue
- URGN $91,871,000.00
- EOI N/A
- Revenue This Year
- URGN $39.80
- EOI N/A
- Revenue Next Year
- URGN $108.94
- EOI N/A
- P/E Ratio
- URGN N/A
- EOI N/A
- Revenue Growth
- URGN 8.98
- EOI N/A
- 52 Week Low
- URGN $3.42
- EOI $14.36
- 52 Week High
- URGN $19.69
- EOI $18.88
- Technical
- Relative Strength Index (RSI)
- URGN 76.29
- EOI 59.59
- Support Level
- URGN $18.37
- EOI $20.70
- Resistance Level
- URGN $19.36
- EOI $21.05
- Average True Range (ATR)
- URGN 1.03
- EOI 0.19
- MACD
- URGN 0.25
- EOI -0.02
- Stochastic Oscillator
- URGN 91.26
- EOI 76.14
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.